Navigation Links
Soligenix to Present at 8th Annual BIO Investor Forum
Date:10/27/2009

PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that its Chief Financial Officer Evan Myrianthopoulos will present a company overview highlighting recent developments at the BIO Investor Forum.

The presentation will take place on Thursday, October 29, 2009 at 1:00 PM PDT at The Palace Hotel in San Francisco, CA.

The Soligenix presentation will be webcast live and archived for later replay. To access the webcast, please visit the company's investor page at http://www.soligenix.com/invest_sec.shtml. The replay will be available 24 hours after the live presentation and will be accessible for 30 days.

About the BIO Investor Forum

The 8th Annual BIO Investor Forum is an international conference featuring late-stage private and emerging public companies. This year's BIO Investor Forum will include healthcare venture and private equity investors, buy-side investors and research analysts, as well as business development executives from leading global pharmaceutical and mature biotechnology companies.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix), formerly known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVH
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
2. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
4. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
5. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
6. Transdel Pharmaceuticals to Present at Two Investor Conferences
7. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 2009 BIOCOM INVESTOR CONFERENCE
8. Advanced Life Sciences to Present at 8th Annual BIO Investor Forum
9. Researchers Present a Novel, Automated, Efficient Environmental Disinfection Technology that Significantly Reduces C. difficile, VRE and MRSA Contamination
10. China Pharma Holdings, Inc. to Present at the Roth China Conference on October 14 at 12:00 pm ET
11. 17th International Process Development Conference to Feature Presentations on Safety, Process Development, Crystallization, PAT, Scale-Up and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
(Date:8/29/2014)... 29, 2014 Local veterinarian, Dr. Keith ... are seeking candidates to participate in an investigational study ... The ultimate goal of this study is to determine ... one or two arthritically affected joints can help reduce ... Candidates for the current investigational study must be older ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Due to a ... last week, the Adult Stem Cell Technology Center, LLC ( ... support stem cell therapy research that might benefit ALS patients. ... cells for new stem cell technologies and therapeutic applications, FRC ... Ice Bucket Challenge donors who wish not to support ...
Breaking Biology Technology:Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3
... Surrey have developed microchips capable of quickly and cheaply ... scientists announced today (Wednesday 5 September 2007) at the ... of Edinburgh, UK, which runs from 3-6 September 2007. ... be able to test clinical samples from their patients ...
... the 12th World Conference on Lung Cancer in ... - YM BioSciences Inc.,(AMEX: YMI , TSX: ... and commercializes differentiated products for patients worldwide,today announced ... of,the Phase I part of a Phase I/II ...
... Newsmakers in the Biotech,Industry, Bank of America Investment, and UBS Global ... ... SEATTLE, Sept. 4 Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ) ... of Trubion, will present an overview,of the company at three September ...
Cached Biology Technology:Quick microchip test for dangerous antibiotic resistant bacteria 2YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 2YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 3YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 4YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION 5Trubion Pharmaceuticals to Present at Upcoming Investor Conferences 2
(Date:8/29/2014)... Boulder, Colo., USA - The rise of the Tibetan ... on Earth -- is important for both its profound ... In this study published in GSA Bulletin , ... -- "clumped" isotope thermometry -- using modern and fossil ... Zhada basin in southwestern Tibet. , Views range ...
(Date:8/28/2014)... of America (ESA) is pleased to announce the selection ... the Society. Honorary Membership acknowledges those who have served ... in the affairs of the Society that has reached ... by the ESA Governing Board and then voted on ... at the Awards Ceremony at Entomology 2014, ESA,s Annual ...
(Date:8/28/2014)... an expansion of marine protected areas is needed to ... According to investigators from the Wildlife Conservation Society and ... on saving the largest numbers of species, often at ... difficult-to-replace ecological functions. , Many vital ecological ... that also are food for millions of people. ...
Breaking Biology News(10 mins):Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... Scientists at The University of Nottingham and the Wellcome Trust ... that control the three key stages in the life cycle ... third of these switches can be disrupted in some way. ... and the Medical Research Council (MRC) is a significant breakthrough ...
... journal, Science Translational Medicine , examines the structures ... commentary has been written by researchers from the National ... (BRC) at Guy,s and St Thomas, and King,s College ... Government and charitable investment in translational research taking place ...
... Health Sciences Center New Orleans has been awarded $12 ... Health to conduct research on diseases like prostate and ... herpes infections, as well as to support the development ... round of funding for a $10.6 million Center of ...
Cached Biology News:Malaria research begins to bite 2Malaria research begins to bite 3Strategies for translational research in the UK 2LSUHSC awarded $12 million for cancer, infectious diseases research & research pipeline 2LSUHSC awarded $12 million for cancer, infectious diseases research & research pipeline 3
... consumable measurement plate for QPatch. ... controlled measurement sites. Each measurement ... flow channel system that enables ... and compound applications necessary for ...
... is a compact and self-contained multichannel ... a unique flow-through device, which allows ... wash system. Optional refill system ... Will be upgradable to with ...
This kit is designed to select cells labeled with phycoerythrin- (PE-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... iLink makes it easy to supply microplates, ... Developed with operator convenience in mind, iLink ... ease of use. The iLink software is ... assays or sub-assays, that can be copied ...
Biology Products: